Division of Hematologic Malignancies 1 (DHM1)

Division of Hematologic Malignancies 1 (DHM1) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologic Licensing Applications (BLAs) for Acute Leukemia and Myelodysplasia and Chronic Myeloid Leukemia.

Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news